Deutsche Bank’s Monte Rosa Therapeutics GLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$787K Buy
47,862
+14,754
+45% +$282K ﹤0.01% 2324
2025
Q4
$519K Buy
33,108
+8,537
+35% +$115K ﹤0.01% 2546
2025
Q3
$182K Buy
24,571
+5,941
+32% +$31.5K ﹤0.01% 3110
2025
Q2
$84K Sell
18,630
-6,220
-25% -$27.7K ﹤0.01% 3312
2025
Q1
$115K Sell
24,850
-4,214
-14% -$25.8K ﹤0.01% 3151
2024
Q4
$202K Buy
29,064
+6,633
+30% +$49.8K ﹤0.01% 3089
2024
Q3
$119K Buy
22,431
+11,571
+107% +$58.4K ﹤0.01% 3155
2024
Q2
$40.6K Sell
10,860
-2,528
-19% -$12.9K ﹤0.01% 3359
2024
Q1
$94.4K Sell
13,388
-571
-4% -$3.39K ﹤0.01% 3195
2023
Q4
$78.9K Hold
13,959
﹤0.01% 3325
2023
Q3
$66.9K Hold
13,959
﹤0.01% 3335
2023
Q2
$95.6K Sell
13,959
-12,319
-47% -$79.7K ﹤0.01% 3294
2023
Q1
$205K Buy
26,278
+305
+1% +$2.12K ﹤0.01% 2988
2022
Q4
$198K Buy
25,973
+2,481
+11% +$20.7K ﹤0.01% 2984
2022
Q3
$192K Buy
23,492
+10,026
+74% +$92.1K ﹤0.01% 2970
2022
Q2
$130K Sell
13,466
-2,584
-16% -$26K ﹤0.01% 3387
2022
Q1
$225K Buy
16,050
+9,040
+129% +$126K ﹤0.01% 3198
2021
Q4
$143K Sell
7,010
-688
-9% -$14.4K ﹤0.01% 3536
2021
Q3
$171K Buy
+7,698
New +$221K ﹤0.01% 3647

Other funds holding GLUE

Deutsche Bank's GLUE Position: Q1 2026 in Review

Deutsche Bank increased its Monte Rosa Therapeutics (GLUE) stake by 45% in Q1 2026, buying an estimated $282K and bringing the position to 47,862 shares worth $787K. The position accounts for ﹤0.01% of the portfolio, ranked #2324.

Deutsche Bank first reported a position in GLUE in Q3 2021 and has held it in 19 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Deutsche Bank held 47,862 shares of Monte Rosa Therapeutics worth $787K as of Q1 2026.
  • Deutsche Bank bought 14,754 Monte Rosa Therapeutics shares in Q1 2026, an estimated $282K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #2324 holding.
  • Deutsche Bank first reported a position in Monte Rosa Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.